Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models

Grunewald, S; Politz, O; Bender, S; Heroult, M; Lustig, K; Thuss, U; Kneip, C; Kopitz, C; Zopf, D; Collin, MP; Boemer, U; Ince, S; Ellinghaus, P; Mumberg, D; Hess-Stumpp, H; Ziegelbauer, K

Politz, O (reprint author), Bayer AG, Res & Dev, Pharmaceut, Muellerstr 178, D-13353 Berlin, Germany.

INTERNATIONAL JOURNAL OF CANCER, 2019; 145 (5): 1346